ArticleCancer science2014
Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone.
Article in Cancer science, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 44 citations in OpenAlex.
- Preparation and Preclinical Evaluation ofMolecules (Basel, Switzerland) · 2024Article
- Review
- Article
- Isocitrate DehydrogenaseBritish journal of biomedical science · 2022Article
- Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations.Cell reports. Medicine · 2021Review
- Isocitrate dehydrogenase gene variants in cancer and their clinical significance.Biochemical Society transactions · 2021Review
- The oncometabolite R-2-hydroxyglutarate dysregulates the differentiation of human mesenchymal stromal cells via inducing DNA hypermethylation.BMC cancer · 2021Article
- Quantitative Analysis of Oncometabolite 2-Hydroxyglutarate.Advances in experimental medicine and biology · 2021Article
- Solid papillary carcinoma with reverse polarity of the breast harbors specific morphologic, immunohistochemical and molecular profile in comparison with other benign or malignant papillary lesions of the breast: a comparative study of 9 additional cases.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2018Article
- Review
- Prevalence of the single-nucleotide polymorphism rs11554137 (IDH1Scientific reports · 2018Article
- Article
- Development of RAP Tag, a Novel Tagging System for Protein Detection and Purification.Monoclonal antibodies in immunodiagnosis and immunotherapy · 2017Article
- Role of mitochondrial dysfunction in cancer progression.Experimental biology and medicine (Maywood, N.J.) · 2016Review
- IDH Mutation Analysis in Ewing Sarcoma Family Tumors.Journal of pathology and translational medicine · 2015Article
- Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclast-rich mimics.The journal of pathology. Clinical research · 2015Article
- Mutant IDH is sufficient to initiate enchondromatosis in mice.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Insight into the pathogenesis and nature of Central Giant Cell Lesions of the Jaws.Medicina oral, patologia oral y cirugia bucal · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Giant cell tumors of bone (GCTB) are benign and locally destructive tumors that include osteoclast-type multinuclear giant cells. No available treatment is definitively effective in curing GCTB, especially in surgically unresectable cases. Isocitrate dehydrogenase (IDH) mutations have been reported not only in gliomas and acute myeloid leukemias, but also in cartilaginous tumors and osteosarcomas. However, IDH mutations in GCTB have not been investigated. The IDH mutations are remarkably specific to arginine 132 (R132) in IDH1 and arginine 172 (R172) or arginine 140 (R140) in IDH2; IDH1/2 mutations are known to convert α-ketoglutarate to oncometabolite R(-)-2-hydroxyglutarate. We recently reported that the most frequent IDH mutation in osteosarcomas is IDH2-R172S, which was detected by MsMab-1, a multispecific anti-IDH1/2 mAb. Herein, we newly report the IDH mutations in GCTB, which were stained by MsMab-1 in immunohistochemistry. DNA direct sequencing and subcloning identified IDH mutations of GCTB as IDH2-R172S (16 of 20; 80%). This is the first report to describe IDH mutations in GCTB, and MsMab-1 can be anticipated for use in immunohistochemical determination of IDH1/2 mutation-bearing GCTB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.